KEY ACCOUNT MANAGER
Pubblicato il 20-10-2026 - Pharma Point in Roma
Business unitMarket Access; SalesSediItalia/Emilia Romagna; Italia/MarchePharma Point, on behalf of Cytokinetics, is looking for a Key Account Manager (KAM) Emilia Romagna - Marche (Bologna) to join the Commercial team in Italy.Company OverviewCytokinetics is a late-stage biopharmaceutical company pioneering muscle biology to develop therapies for cardiovascular and neuromuscular diseases.As the company prepares for the Italian launch of aficamten for obstructive hypertrophic cardiomyopathy (oHCM), Cytokinetics is seeking a Key Account Manager (KAM).Roles and ResponsibilitiesCreate customer targets, sales plans and action plans in line with country strategy and in agreement with the line manager.Manage customer contacts through one-to-one meetings, virtual calls, group meetings, congresses and other relevant interactions with treating physicians, particularly cardiologists, and their wider multidisciplinary teams, including hospital pharmacists and administrators.Drive brand awareness and product adoption for aficamten through the delivery of key product messages,
compelling clinical data discussions, effective handling of competitor messages and relationship building with agreed target groups.Achieve agreed sales and volume targets for aficamten.Utilize the CRM system to support the sales process and maintain data in a timely manner, as required.Implement the Cytokinetics commercial strategy within the agreed promotional and cost budget.Conduct regular territory analyses to develop an in-depth understanding of customers, competitor landscape and activities, as well as trends in sales and market share.Develop and maintain a detailed mapping of the territory, including treating physicians, multidisciplinary teams, hospital and administrative stakeholders and key accounts, to guide resource allocation, call planning and account prioritization.Develop an in-depth understanding of the oHCM patient journey, from symptom onset and diagnosis through referral, treatment ini